Back to top
more

Bausch Health (BHC)

(Delayed Data from NYSE)

$8.71 USD

8.71
2,081,596

+0.09 (1.04%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $8.72 +0.01 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich

Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.

Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down

Bausch (BHC) declines as it misses on earnings and sales in the first quarter.

Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Bausch Health (BHC) Misses Q1 Earnings and Revenue Estimates

Bausch (BHC) delivered earnings and revenue surprises of -30.67% and 0.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Bausch Health (BHC) Q1 Earnings Expected to Decline

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Bausch Health (BHC) Stock Options

Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.

Bausch Health's (BHC) Q4 Earnings & Sales Beat, Shares Up

Bausch (BHC) reports an increase in earnings and sales in the fourth quarter as the company???s business revives in the second half.

Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates

Bausch (BHC) delivered earnings and revenue surprises of 10.87% and 3.35%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Perion Network and West Fraser Timber have been highlighted as Zacks Bull and Bear of the Day

Perion Network and West Fraser Timber are part of the Zacks Bull and Bear of the Day article.

Kinjel Shah headshot

Drug, Biotech Stocks' Q4 Earnings on Feb 23: MRNA, BHC & More

Let us look at four drug and biotech companies, MRNA, BHC, ALNY and AGIO, which are gearing up for their earnings release.

Bausch (BHC) Stock Jumps 19.3%: Will It Continue to Soar?

Bausch (BHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

New Strong Sell Stocks for December 9th

ACCO, BHC and HOUS have been added to the Zacks Rank #5 (Strong Sell) List on December 9, 2022.

Bausch (BHC) Q3 Earnings & Sales Miss, Guidance Lowered

Bausch (BHC) Q3 earnings and sales decline year over year due to the unfavorable impact of foreign exchange rates. The company also lowers its annual guidance.

Bausch Health (BHC) Misses Q3 Earnings and Revenue Estimates

Bausch (BHC) delivered earnings and revenue surprises of -17.39% and 2.21%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Bausch Health (BHC) Q3 Earnings Expected to Decline

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Bausch (BHC) Stock?

Investors need to pay close attention to Bausch (BHC) stock based on the movements in the options market lately.

Why Is Bausch (BHC) Up 23% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision

Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.

Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down

Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.

Bausch Health (BHC) Q2 Earnings and Revenues Miss Estimates

Bausch (BHC) delivered earnings and revenue surprises of -38.20% and 3.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More

Let us look at four drug and biotech companies, EXEL, BHC, CPRX and AXSM, which are gearing up for their earnings release.

Supernus Pharmaceuticals (SUPN) Q2 Earnings Lag Estimates

Supernus (SUPN) delivered earnings and revenue surprises of -53.33% and 2.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of 4.76% and 21.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Bausch Health (BHC) Q2 Earnings?

An update on the IPO of Solta Medical and regular top-line and bottom-line numbers will grab investors' attention when Bausch Health (BHC) reports Q2 results.

Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.